

Initiation of Phase I Clinical Trial of NIB-102/TAK-102

We are pleased to announce that the enrollment of patients in the Phase I clinical trial of NIB-102, a pipeline licensed from our company to Takeda Pharmaceutical Company Limited (hereafter Takeda) and designated as TAK-102, has started.

NIB-102/TAK-102 is CAR-T cell equipped with our core technology, “PRIME” (proliferation inducing and migration enhancing) for the treatment of solid tumors by targeting GPC3 antigen.

Takeda holds exclusive rights to develop and commercialize NIB-102/TAK-102 worldwide. For more details of the clinical trials, please refer to the following registration information: <https://clinicaltrials.gov/ct2/show/NCT04405778>

This is the first clinical trial of the pipeline equipped with our PRIME technology. We will continuously promote Research and Development to ensure and deliver effective therapies for cancer patients at the earliest possible date.